NEW YORK (GenomeWeb News) – While 2013 was a very good year in general for the stock market, biotech stocks, including those of omics tools and molecular diagnostics firms, provided a particularly strong return for investors.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.